Zosuquidar

Zosuquidar
Systematic (IUPAC) name

(2R)-1-{4-[(1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl}-3-(quinolin-5-yloxy)propan-2-ol
Identifiers
CAS Number	167354-41-8^N
ATC code	None
PubChem	CID 153997
ChemSpider	24599682^Y
UNII	AB5K82X98Y^Y
KEGG	D06387^Y
ChEMBL	CHEMBL444172^Y
Chemical data
Formula	C₃₂H₃₁F₂N₃O₂
Molar mass	527.61 g/mol
SMILES Cl.Cl.Cl.FC4(F)[C@@H]3c1ccccc1C(c2c(cccc2)[C@@H]34)N5CCN(CC5)C[C@@H](O)COc7c6cccnc6ccc7
InChI InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1^Y Key:IHOVFYSQUDPMCN-DBEBIPAYSA-N^Y
^NY (what is this?) (verify)

Zosuquidar is an experimental antineoplastic drug currently under development. It has completed Phase 3 clinical trials in the United States. It inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.

References

This article is issued from Wikipedia - version of the Wednesday, April 08, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.